miR-520h is crucial for DAPK2 regulation and breast cancer progression.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Development of an anoikis-related gene signature and prognostic model for predicting the tumor microenvironment and response to immunotherapy in colorectal cancer.Frontiers in immunology · 2024
   Article
2. Circular RNA circ_SKA3 enhances gastric cancer development by targeting miR-520h.Histology and histopathology · 2023
   Article
3. circNFATC3 facilitated the progression of oral squamous cell carcinoma via the miR-520h/LDHA axis.Open medicine (Warsaw, Poland) · 2023
   Article
4. Hsa_Circ_0001860 Promotes Smad7 to Enhance MPA Resistance in Endometrial CancerFrontiers in cell and developmental biology · 2021
   Article
5. Regulation of epithelial-mesenchymal transition through microRNAs: clinical and biological significance of microRNAs in breast cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
   Review

Corrections and comments

• Erratum for
  miR-520h is crucial for DAPK2 regulation and breast cancer progression.2016

Authors and funding

14 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract